The SARS-CoV-2 epidemic, which killed more than 15 million people worldwide, in addition to high mortality, brought a series of post-COVID consequences. According to the current literature, the main persistent symptoms after infection are fatigue, dyspnea and muscle pain. Another important possible damage, still little discussed in the literature, refers to the association of SARS-CoV 2 infection with the prevalence of Urinary Incontinence (UI). This condition is more prevalent among women, ranging from 25 to 45% in the global population, affecting the health and quality of life of this population.

To identify the prevalence of UI in patients infected with SARS-CoV 2 after hospital discharge and describe the sociodemographic and clinical profile of these subjects.

Descriptive and cross-sectional study. The population consisted of individuals after hospital discharge due to SARS-CoV-2 infection. Data collection was carried out via telephone call by a previously trained researcher, after hospital discharge, using a structured instrument asking sociodemographic data, previous conditions, hospitalization conditions, UI assessment and use of the Functional Status Scale (PCFS), from September 2021 to October 2022. The sample size was calculated by using the study by Dhar et al. (2020) as a reference. Adopting a significance level of 85%, acceptable error of 5% and a prevalence rate of 7%, indicating a sample size of 54 subjects. To verify the association of variables with the presence of urogenital disorders, the Chi-Square, Fisher's Exact, Student's t, Mann-Whitney and Multivariate Analysis tests were applied.

The sample consisted of 32 women (56.4 ±11.3 years) and 27 men (49.5 ±10.7 years), the women being 7 years older (p=0.022). The prevalence of UI in the sample was 15.25%, with only women affected. The presence of UI pre versus post hospitalization for SARCoV-2 did not change (15.25% and 15.25%, respectively). During hospitalization, 28.8% of the sample required care in the Intensive Care Unit (ICU), with an average of 26.4 ± 40 days of hospitalization. As for the disability condition evaluated with the PCFS scale, grades 3 and 4 (moderate and severe) were identified in 44.1% of the individuals. In the multivariate analysis, in the model with different variables (age, hypertension, kidney disease, insomnia and emotional disorders), only the emotional aspects showed a significant association between the outcomes (p=0.034).

The prevalence of UI among the assessed sample did not change after hospital discharge due to hospitalization due to COVID-19. Women had a higher prevalence of UI, with emotional aspects being the variable associated with outcomes.

The consequences of COVID-19, especially in post-discharge patients, need to be better investigated. Some limitations, such as sample size and patient profile, may have influenced the results of this study.